Share：
Share this content in WeChat
X
[Chinese][PDF]850130
• CLINICAL ARTICLE •
Radiomics features based on pharmacokinetic dynamic contrast-enhanced magnetic resonance imaging for identifying triple negative breast cancer
WANG Chunhua  LUO Hongbing  LIU Yuanyuan  CHEN Xiaoyu  QING Haomiao  WANG Min  ZHANG Xin  XU Guohui  REN Jing  ZHOU Peng 

Cite this article as: Wang CH, Luo HB, Liu YY, et al. Radiomics features based on pharmacokinetic dynamic contrast-enhanced magnetic resonance imaging for identifying triple negative breast cancer[J]. Chin J Magn Reson Imaging, 2021, 12(2): 29-33. DOI:10.12015/issn.1674-8034.2021.02.007.


[Abstract] Objective To study the evaluation of radiomics features based on pharmacokinetic dynamic contrast-enhanced MRI (DCE-MRI) for differentiating triple negative (TN) breast cancer from other molecular subtype breast cancers. Materials andMethods This retrospective study included 85 patients with breast cancer who underwent pharmacokinetic DCE-MRI before treatment. Breast cancers were classified into four molecular subtypes by immunohistochemistry, including Luminal (n=39), human epidermal growth factor receptor 2 (HER-2) overexpression (n=16) and TN (n=30). Radiomics features of whole breast cancer were extracted from pharmacokinetic quantitative and enhanced images, respectively. Spearman correlation and least absolute shrinkage and selection operator (LASSO) were used for feature selection in R. Logistic model was used for classification of TN vs. luminal, TN vs. HER-2 overexpression, and TN vs. non-TN. Receiver operating characteristics curve and area under curve (AUC) were obtained. Five-fold cross validation was used to verify classification performance.Results For the TN vs. luminal breast cancer, 6 optimal features were selected. Accuracy, and AUC were 0.783 and 0.865, respectively. For the TN vs. HER-2 overexpression breast cancer, 14 optimal features were selected. Accuracy and AUC were 0.870 and 0.923, respectively. For the TN vs. non-TN breast cancer, 17 optimal features were selected. Accuracy and AUC were 0.847 and 0.913, respectively.Conclusions The rediomics features can help to differentiate TN from other molecular subtype breast cancer.
[Keywords] breast tumor；triple negative；magnetic resonance imaging；dynamic enhancement；pharmacokinetics；radiomics

WANG Chunhua1   LUO Hongbing1   LIU Yuanyuan1   CHEN Xiaoyu1   QING Haomiao1   WANG Min1   ZHANG Xin2   XU Guohui1   REN Jing1   ZHOU Peng1*  

1 Department of Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China

2 GE Healthcare, PDx, IPM, Shanghai 201203, China

Zhou P, E-mail: penghyzhou@126.com

Conflicts of interest   None.

ACKNOWLEDGMENTS This work was part of National Key Research and Development Program (No. 2017YFC0109405) and the Applied Basic Research Foundation of Science and Technology Department of Sichuan Province (No. 2019YJ0585).
Received  2020-08-07
Accepted  2021-01-12
DOI: 10.12015/issn.1674-8034.2021.02.007
Cite this article as: Wang CH, Luo HB, Liu YY, et al. Radiomics features based on pharmacokinetic dynamic contrast-enhanced magnetic resonance imaging for identifying triple negative breast cancer[J]. Chin J Magn Reson Imaging, 2021, 12(2): 29-33. DOI:10.12015/issn.1674-8034.2021.02.007.

1
Xiu M, Zhang P. Therapeutic pattern and progress of neoadjuvant treatment for early stage triple-negative breast cancer[J]. Cancer Res Prev Treat, 2020, 47(2): 129-134. DOI: 10.3971/j.issn.1000-8578.2020.19.0451.
2
Cao XS, Cong BB. The progress of treatment for triple-negative breast cancer in the era of precision medicine[J]. Chin Oncol, 2019, 29(12): 971-976. DOI: 10.19401/j.cnki.1007-3639.2019.12.009.
3
Li Z, Ai T, Hu Y, et al. Application of whole-lesion histogram analysis of pharmacokinetic parameters in dynamic contrast-enhanced MRI of breast lesions with the CAIPIRINHA-Dixon-TWIST-VIBE technique[J]. J Magn Reson Imaging, 2018, 47(1): 91-96. DOI: 10.1002/jmri.25762.
4
Nagasaka K, Satake H, Ishigaki S, et al. Histogram analysis of quantitative pharmacokinetic parameters on DCE-MRI: correlations with prognostic factors and molecular subtypes in breast cancer[J]. Breast Cancer, 2019, 26(1): 113-124. DOI: 10.1007/s12282-018-0899-8.
5
Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-2795. DOI: 10.1200/JCO.2009.25.6529.
6
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.
7
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15Pt 1): 4429-4434. DOI: 10.1158/1078-0432.ccr-06-3045.
8
Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440. DOI: 10.1016/j.ccell.2019.02.001.
9
Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings[J]. Radiology, 2009, 250(3): 638-647. DOI: 10.1148/radiol.2503081054.
10
Lee YJ, Youn IK, Kim SH, et al. Triple-negative breast cancer: Pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence[J]. Magn Reson Imaging, 2020, 66: 36-41. DOI: 10.1016/j.mri.2019.10.001.
11
Li LH, Liu WH, Wang R, et al. Correlation of quantitative perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast carcinoma[J]. Chin J Radiol, 2016, 50(5): 329-333. DOI: 10.3760/cma.j.issn.1005-1201.2016.05.003.
12
Zhao ZJ, Jin GG, Wang CZ, et al. Changes of dynamic contrast-enhanced MRI quantitative parameters volume transfer (Ktrans) and rate constant (Kep) in patients with different molecular subtypes of breast cancer[J]. Pract J Cancer, 2019, 34(10): 1669-1672. DOI: 10.3969/j.issn.1001-5930.2019.10.029.
13
Luo HB, Wang M, Zhou P, et al. The diagnostic features of quantitative and semi-quantitative parameters obtained from dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) in human brast lesions[J]. J Cancer Control Treat, 2016, 29(4): 199-204. DOI: 10.3969/j.issn.1674-0904.2016.04.002.
14
Xie T, Zhao Q, Fu C, et al. Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on multiparametric MR imaging[J]. Eur Radiol, 2019, 29(5): 2535-2544. DOI: 10.1007/s00330-018-5804-5.
15
Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4): 441-446. DOI: 10.1016/j.ejca.2011.11.036.
16
Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data[J]. Radiology, 2016, 278(2): 563-577. DOI: 10.1148/radiol.2015151169.
17
Chitalia RD, Kontos D. Role of texture analysis in breast MRI as a cancer biomarker: A review[J]. J Magn Reson Imaging, 2019, 49(4): 927-938. DOI: 10.1002/jmri.26556.
18
Pinker K, Chin J, Melsaether AN, et al. Precision medicine and radiogenomics in breast cancer: New approaches toward diagnosis and treatment[J]. Radiology, 2018, 287(3): 732-747. DOI: 10.1148/radiol.2018172171.
19
Agner SC, Rosen MA, Englander S, et al. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study[J]. Radiology, 2014, 272(1): 91-99. DOI: 10.1148/radiol.14121031.
20
Wu PQ, Zhao K, Wu L, et al. Correlation of radiomic features based on diffusion weighted imaging and dynamic contrast-enhancement MRI with molecular subtypes of breast cancer[J]. Chin J Radiol, 2018, 52 (5): 338-343. DOI: 10.3760/cma.j.issn.1005-1201.2018.05.004.
21
Leithner D, Horvat JV, Marino MA, et al. Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results[J]. Breast Cancer Res, 2019, 21(1): 106. DOI: 10.1186/s13058-019-1187-z.
22
Wang SJ, Fan M, Zhang J, et al. Association between DCE-MRI features and molecular subtypes in breast cancer[J]. Chin J Biomed Engin, 2016, 35(5): 533-540. DOI: 10.3969/j.issn.0258-8021.2016.05.004.
23
Wang J, Kato F, Oyama-Manabe N, et al. Identifying triple-negative breast cancer using background parenchymal enhancement heterogeneity on dynamic contrast-enhanced MRI: A pilot radiomics study[J]. PLoS One, 2015, 10(11): e0143308. DOI: 10.1371/journal.pone.0143308.

PREV 3.0 T MRI features of breast cancer in different molecular types
NEXT The preliminary study on the parameter optimization of IVIM-DWI pulse sequence in gastric cancer patients with 3.0 T MR
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn